New pill targets Cancer's DNA repair in advanced tumor trial
NCT ID NCT05898399
Summary
This study is testing a new oral drug called ART6043 for people with advanced or metastatic solid tumors. It will check the safety and early signs of effectiveness of ART6043 when taken by itself and when combined with an existing cancer drug, olaparib. The trial will enroll about 220 participants, focusing on patients whose cancers have specific genetic weaknesses in DNA repair.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jefferson University Hospitals - Kimmel Cancer Center
Philadelphia, Pennsylvania, 17107, United States
-
Mary Crowley Cancer Center - Clinic
Dallas, Texas, 75251, United States
-
Memorial Sloan-Kettering Cancer Center (MSKCC)
New York, New York, 10065-6800, United States
-
SCRI oncology partners
Nashville, Tennessee, 37203, United States
-
South Texas Accelerated Research Therapeutics (START) - Midwest
Grand Rapids, Michigan, 49546, United States
-
Stephenson Cancer Center - Oncology
Oklahoma City, Oklahoma, 73104, United States
-
The University of Texas - MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.